<DOC>
	<DOCNO>NCT02720666</DOCNO>
	<brief_summary>This study open single-center Phase I clinical research patient advance pancreatic cancer , evaluate adverse reaction tolerance K-001 , determine safe reasonable dosage dose regimen .</brief_summary>
	<brief_title>K-001 Treatment Advanced Pancreatic Cancer : Clinical Trial Monotherapy 's Tolerability</brief_title>
	<detailed_description>According past experience toxicology study clinical test , K-001 dose 2700mg/day good safety profile human body . Upon observation , pancreatic cancer patient receive medication 2160mg/day ( 1080mg BID ) good therapeutic efficacy , sign significant toxicity . Dosing regimen : Phase I clinical test : maximum dose monotherapy 2700mg/day . Four group repeat administration monotherapy , least 3 patient group . Group A : 2700mg/d ( 1350mg BID ) ; Group B : 3240mg/d ( 1620mg BID ) ; Group C : 3780mg/d ( 1890mg BID ) ; Group D : 4320mg/d ( 2160mg BID ) . Twice day , take warm water empty stomach ; 4 week ' administration group . In case severe adverse reaction associate test drug , half participant show adverse reaction Ⅲ level , test terminate . The maximum dosage cause above-described situation shall consider maximum tolerate dose biologically effective dose . After test , continuous medication shall give upon request patient .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Diseaserelated criterion inclusion : 1 . Based histodiagnosis cytodiagnosis ; 2 . Locally advanced metastatic pancreatic adenocarcinoma ; 3 . Failure standard treatment , ＞28 day last chemotherapy ; 4 . Patients suitable give standard treatment ; 5 . At least one lesion measurable accord RECIST V 1.0 criterion ; 6 . ECOG score : 0～1 ; 7 . Expected survival : ≥3 month ; Haematological , biochemical organ function : 8 . Hematological index : Absolute neutrophil count : ≥1.5×109/L ; Platelet count : ≥80×109/L ; Hemoglobin : ≥9.0 g/dL . 9 . Total bilirubin : ≤1.5 x ULN , albumin : ≥3.0g/dL ; 10 . Patients without liver metastasis : ALT ( SGPT ) &amp; AST ( SGOT ) ≤3.0 x ULN Patients liver metastasis : ALT ( SGPT ) &amp; AST ( SGOT ) ≤5.0 x ULN ; 11 . Renal function : serum creatinine ≤ 1.5xULN , Ccr ≥ 60ml/min ( CockcroftGault ) ; General criterion inclusion : 12 . Age : 18～70 ; 13 . Letter Consent sign patient his/her legal representative : 14 . Women childbearing age must urine pregnancy test within 7 day start treatment , negative result shall include group . Male female patient childbearing age agree use reliable method contraception participate study well 90 day ( least ) withdrawal . Diseaserelated criteria exclusion : 1 . Patients pancreatic tumor adenocarcinoma ; 2 . Having receive radiotherapy his/her target lesion prior study , progress ; 3 . Known presence brain metastasis leptomeningeal metastasis ; 4 . With Vater 's ampulla cancer bile duct cancer ; 5 . Partial complete intestinal obstruction ; 6 . History malignancy past five year , except : A consecutive 5year diseasefree survival single surgery malignancy ; Cured basal cell carcinoma cure cervical carcinoma situ . General criteria exclusion : 7 . Pregnant breastfeeding woman ; 8 . Any unstable systemic disease , include : active infection ; hypertension uncontrollable medication ( ≥160/100mmHg ) ; unstable angina , angina onset within last three month ; congestive heart failure ( ≥level II accord New York Heart Association [ NYHA ] , see Annex 4 ) ; myocardial infarction occur within 1 year enrollment ; severe arrhythmia require medical treatment ; mental disorder , etc . ; 9 . Presence active hepatitis B ( history hepatitis B infection , whether without medication , HBV DNA≥104 copy number ≥2000u/ml ) HCVAb positive ; know HIVpositive patient ( clinical sign symptom suggest exemption HIV test HIVinfected individual ) ; 10 . Having receive following treatment within specific time period inclusion : Having major surgery within 4 week inclusion ; Having receive expanded scope radiotherapy within 4 week , receive limited scope radiotherapy within 2 week inclusion ; Having participate therapeutic/interventive clinical trial within 4 week inclusion , take part ongoing trial . 11 . With CTCAE toxicity level II ( exclude hair loss skin pigmentation ) , uncured cause previous treatment ; 12 . Not fit study , conceive researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>